Welcome to our dedicated page for SCYNEXIS news (Ticker: SCYX), a resource for investors and traders seeking the latest updates and insights on SCYNEXIS stock.
SCYNEXIS, Inc. develops therapies for severe rare diseases and difficult-to-treat fungal infections. The company’s updates center on SCY-770, a clinical-stage oral direct AMPK activator for autosomal dominant polycystic kidney disease, and SCY-247, a second-generation triterpenoid antifungal therapy in development for invasive candidiasis and prophylaxis of invasive fungal disease.
SCYNEXIS news also covers its fungerp antifungal platform, FDA designations for SCY-247, scientific presentations, financial results, and corporate actions. The company has licensed ibrexafungerp, including BREXAFEMME® for vulvovaginal candidiasis and reduction in recurrent vulvovaginal candidiasis, to GSK, making collaboration and license-agreement updates a recurring disclosure theme.
SCYNEXIS, a biotechnology company focused on innovative treatments for drug-resistant infections, will participate in two upcoming virtual investor conferences in September 2021. The conferences include the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, featuring an on-demand presentation and one-on-one meetings, and the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, with a live presentation. More information and archived webcasts will be available on their website for 30 days post-event.
SCYNEXIS announced financial results for Q2 2021, showcasing a strong cash position of $112.4 million. The company reported a net income of $1.7 million, reversing a loss of $6.4 million from the previous year. BREXAFEMME, the first FDA-approved antifungal in over 20 years, launched in August 2021, with positive payer engagement. Clinical advancements include completing enrollment in the Phase 3 CANDLE study and ongoing Phase 1 trials for a liposomal IV formulation. The company expects to sustain operations into 2023 driven by anticipated sales of BREXAFEMME.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced the granting of stock options to five new employees, allowing them to purchase a total of 24,500 shares at an exercise price of $6.97 per share, the closing price on July 30, 2021. This grant serves as an incentive for accepting job offers and will vest over a four-year period. SCYNEXIS focuses on developing innovative antifungal treatments, including the recently FDA-approved BREXAFEMME (ibrexafungerp), targeting drug-resistant infections in both community and hospital settings.
SCYNEXIS, Inc. (NASDAQ: SCYX) presented data from two Phase 3 studies (VANISH-303 and VANISH-306) on oral ibrexafungerp for treating vulvovaginal candidiasis (VVC). The studies targeted patients with severe yeast infections and showed ibrexafungerp's efficacy and safety. Results indicated a Clinical Cure Rate of 56.9% for ibrexafungerp compared to 35.7% for placebo (p=0.001). The FDA approved BREXAFEMME® for the treatment of VVC, marking a significant milestone as the first new class of antifungal agent in over 20 years. Further studies are ongoing for recurrent VVC prevention.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced promising presentations for ibrexafungerp at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The data highlight ibrexafungerp's effectiveness against challenging fungal infections, including drug-resistant Candida auris. In vitro studies showed broad activity of ibrexafungerp against 967 clinical isolates in Denmark. From the FURI study, 70% of patients with refractory fungal diseases demonstrated clinical improvement, while 80% of patients in the CARES study achieved a complete response for Candida auris infections.
SCYNEXIS, Inc. (NASDAQ: SCYX) has announced that CFO Eric Francois will present at Ladenburg Thalmann’s virtual Healthcare Conference on July 14, 2021, from 11:00 to 11:25 AM ET. This presentation will highlight the company’s innovative medicines aimed at combating drug-resistant infections, particularly their lead asset, ibrexafungerp. The company recently received FDA approval for BREXAFEMME (ibrexafungerp tablets) on June 1, 2021. The conference webcast will be accessible for three months on the SCYNEXIS website.
SCYNEXIS announced stock options grants for four new employees totaling 18,100 shares at an exercise price of $7.36, aligning with the closing price on June 30, 2021. The options, part of the 2015 Inducement Award Plan, vest over four years, promoting employee retention. This initiative aims to attract talent in the biotech sector, focusing on innovative antifungal treatments.
SCYNEXIS is advancing ibrexafungerp, a drug targeting drug-resistant fungal infections, with FDA approval for BREXAFEMME on June 1, 2021.
SCYNEXIS has announced an update for the commercial launch of BREXAFEMME (ibrexafungerp), the first FDA-approved antifungal in over 20 years, specifically for vaginal yeast infections. The launch call is set for June 29, 2021, at 12 PM ET, featuring key presentations from management and Dr. Michael L. Krychman. BREXAFEMME offers a new treatment option for vulvovaginal candidiasis (VVC) and is contraindicated during pregnancy. This innovative drug demonstrates a favorable safety profile and efficacy against various Candida strains. For more details, visit www.brexafemme.com.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced its participation in the BIO Digital International Convention from June 10-11 and June 14-18, 2021. Dr. Marco Taglietti, the company's CEO, will present the FDA-approved BREXAFEMME® (ibrexafungerp tablets) and discuss late-stage clinical trials for recurrent vaginal yeast infections and life-threatening fungal infections like Candida auris. Attendees can view the presentation ahead of one-on-one meetings starting June 14. SCYNEXIS focuses on developing innovative antifungal treatments aimed at tackling drug-resistant infections.
SCYNEXIS, Inc. has announced an extension of BREXAFEMME's exclusivity under the GAIN Act for a total of 10 years. The FDA's decision to grant 5 years of exclusivity is an addition to existing new chemical entity exclusivity. Moreover, BREXAFEMME is protected by a composition-of-matter patent, which is expected to last until 2035. The company plans to discuss commercial launch strategies on June 29. This antifungal drug is crucial for treating vulvovaginal candidiasis, especially against resistant strains of Candida.